The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo

Biochemical Pharmacology

Volumn 93, Issue 3, 2015, Pages 318-331

  Dornetshuber Fleiss, Rita ^a,b   Heilos, Daniela ^a,b   Mohr, Thomas ^b,c   Richter, Lennart ^d   Süssmuth, Roderich D ^d   Zlesak, Markus ^a,b   Novicky, Astrid ^a,b   Heffeter, Petra ^b,c   Lemmens Gruber, Rosa ^a   Berger, Walter ^b,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Research Platform Translational Cancer Therapy Research   (Austria)

^d TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Angiogenesis; Anticancer; Cyclohexadepsipeptide; Enniatin; Sorafenib; Synergism

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 7; ENNIATIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DEPSIPEPTIDE; ENNIATINS; NICOTINAMIDE; T 2 TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CONTROLLED STUDY; DNA SYNTHESIS; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; ANALOGS AND DERIVATIVES; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; MALE; METABOLISM; PATHOLOGY; PROCEDURES; SCID MOUSE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, SCID; NIACINAMIDE; PHENYLUREA COMPOUNDS; T-2 TOXIN; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921736716     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.12.013     Document Type: Article

References (48)

1. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010;11:1943-55.
2. Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010;45:794-807.
3. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005;331:851-8.
4. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470-81.
5. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-9.
6. Ali R, Mirza Z, Ashraf GMD, Kamal MA, Ansari SA, Damanhouri GA, et al. New anticancer agents: recent developments in tumor therapy. Anticancer Res 2012;32:2999-3005.
7. Dornetshuber R, Heffeter P, Kamyar MR, Peterbauer T, Berger W, Lemmens-Gruber R. Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells. Chem Res Toxicol 2007;20:465-73.
8. Dornetshuber R, Heffeter P, Lemmens-Gruber R, Elbling L, Marko D, Micksche M, et al. Oxidative stress and DNA interactions are not involved in Enniatinand Beauvericin-mediated apoptosis induction. Mol Nutr Food Res 2009;53:1112-22.
9. Dornetshuber R, Heffeter P, Sulyok M, Schumacher R, Chiba P, Kopp S, et al. Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin. Mol Nutr Food Res 2009;53:904-20.
10. Watjen W, Debbab A, Hohlfeld A, Chovolou Y, Kampkotter A, Edrada RA, et al. Enniatins A1, B and B1 from an endophytic strain of Fusarium tricinctum induce apoptotic cell death in H4IIE hepatoma cells accompanied by inhibition of ERK phosphorylation. Mol Nutr Food Res 2008;53:431-40.
11. Sussmuth R, Muller J, von Dohren H, Molnar I. Fungal cyclooligomer depsipeptides: from classical biochemistry to combinatorial biosynthesis. Nat Prod Rep 2011;28:99-124.
12. Jestoi M. Emerging fusarium-mycotoxins fusaproliferin, beauvericin, enniatins, and moniliformin: a review. Crit Rev Food Sci Nutr 2008;48:21-49.
13. Uhlig S, Jestoi M, Parikka P. Fusarium avenaceum - the North European situation. Int J Food Microbiol 2007;119:17-24.
14. Faeste CK, Ivanova L, Uhlig S. In vitro metabolism of the mycotoxin enniatin B in different species and cytochrome p450 enzyme phenotyping by chemical inhibitors. Drug Metab Dispos 2011;39:1768-76.
15. Madry N, Zocher R, Kleinkauf H. Enniatin production by Fusarium oxysporum in chemically defined media. Eur J Appl Microbiol Biotechnol 1983;17:75-9.
16. Shen DW, Cardarelli C, Hwang J, Cornwell M, Richert N, Ishii S, et al. Multiple drug-resistant human KB carcinoma cells independently selected for highlevel resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 1986;261:7762-70.
17. Dornetshuber-Fleiss R, Heffeter P, Mohr T, Hazemi P, Kryeziu K, Seger C, et al. Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. Biochem Pharmacol 2013;86:361-77.
18. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
19. Lotsch D, Steiner E, Holzmann K, Spiegl-Kreinecker S, Pirker C, Hlavaty J, et al. Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis. Oncotarget 2013;4:1904-18.
20. Wang H, Gao P, Zheng J. Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells. Biochem Biophys Res Commun 2014;451:556-61.
21. Takita M, Furuya T, Sugita T, Kawauchi S, Oga A, Hirano T, et al. An analysis of changes in the expression of cyclins A and B1 by the cell array system during the cell cycle: comparison between cell synchronization methods. Cytometry A 2003;55:24-9.
22. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer 2008;7:50-62.
23. Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 2001;4:113-21.
24. Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, et al. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med 2007;5:38.
25. Yeh CT, Rao YK, Ye M, Wu WS, Chang TC, Wang LS, et al. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging. Toxicol Appl Pharmacol 2012;261:31-41.
26. Heffeter P, Atil B, Kryeziu K, Groza D, Koellensperger G, Korner W, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer 2013;49:3366-75.
27. Choo KB, Chong KY. Absence of mutation in the p53 and the retinoblastoma susceptibility genes in primary cervical carcinomas. Virology 1993;193:1042-6.
28. Wesierska-Gadek J, Borza A, Walzi E, Krystof V, Maurer M, Komina O, et al. Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment. J Cell Biochem 2009;106:937-55.
29. del Campo JM, Prat A, Gil-Moreno A, Perez J, Parera M. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 2008;110:S72-6.
30. Gonzalez-Cortijo L, Carballo N, Gonzalez-Martin A, Corraliza V, Chiva de Agustin L, Lapuente Sastre F, et al. Novel chemotherapy approaches in chemoradiation protocols. Gynecol Oncol 2008;110:S45-8.
31. Mao WF, Shao MH, Gao PT, Ma J, Li HJ, Li GL, et al. The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. Acta Pharmacol Sin 2012;33:1311-8.
32. Huynh TT, Rao YK, Lee WH, Chen HA, Do-Quyen Le T, Tzeng DT, et al. Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/beta-catenin signaling pathway and epithelial-mesenchymal transition. Toxicol In Vitro 2014;28:552-61.
33. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005;28:249-68.
34. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-2.
35. Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol 2011;17:3922-32.
36. Zhao W, Zhang T, Qu B, Wu X, Zhu X, Meng F, et al. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer Drugs 2011;22:79-88.
37. Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, et al. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Mol Cancer 2014;13:7.
38. Thornton TM, Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci 2009;5:44-51.
39. Rumora L, Grubisic TZ. A journey through mitogen-activated protein kinase and ochratoxin A interactions. Arh Hig Rada Toksikol 2009;60:449-56.
40. Kruber P, Trump S, Behrens J, Lehmann I. T-2 toxin is a cytochrome P450 1A1 inducer and leads to MAPK/p38-but not aryl hydrocarbon receptor-dependent interleukin-8 secretion in the human intestinal epithelial cell line Caco-2. Toxicology 2011;284:34-41.
41. Lucioli J, Pinton P, Callu P, Laffitte J, Grosjean F, Kolf-Clauw M, et al. The food contaminant deoxynivalenol activates the mitogen activated protein kinases in the intestine: interest of ex vivo models as an alternative to in vivo experiments. Toxicon 2013;66:31-6.
42. Song P, Wei JX, Wang HCR. Distinct roles of the ERK pathway in modulating apoptosis of Ras-transformed and non-transformed cells induced by anticancer agent FR901228. FEBS Lett 2005;579:90-4.
43. Kang S, Kim HS, Seo SS, Park SY, Sidransky D, Dong SM. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol 2007;105:662-6.
44. Chuang SM, Wang IC, Yang JL. Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium. Carcinogenesis 2000;21:1423-32.
45. Murtagh J, Lu H, Schwartz EL. Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation. Cancer Res 2006;66:8192-9.
46. Samarzija I, Sini P, Schlange T, Macdonald G, Hynes NE. Wnt3a regulates proliferation and migration of HUVEC via canonical and non-canonical Wnt signaling pathways. Biochem Biophys Res Commun 2009;386:449-54.
47. Thevenard J, Ramont L, Devy J, Brassart B, Dupont-Deshorgue A, Floquet N, et al. The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration. Int J Cancer 2010;126:1055-66.
48. Zhan J, Burns AM, Liu MX, Faeth SH, Gunatilaka AA. Search for cell motility and angiogenesis inhibitors with potential anticancer activity: beauvericin and other constituents of two endophytic strains of Fusarium oxysporum. J Nat Prod 2007;70:227-32.